AT9283是一种多靶点激酶抑制剂，包括Aurora A、Aurora B、JAK3、JAK2和Abl，IC₅₀分别为3 nM, 3 nM, 1.1 nM, 1.2 nM和4 nM。据报道，AT9283对白血病细胞、骨髓增殖性疾病和多种实体瘤细胞系具有疗效。

参考文献

[1]. Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. J Med Chem. 2009 Jan 22;52(2):379-88.

[2]. Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005.

[3]. Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃干燥保存，避免反复冻融。